Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × Trastuzumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 556 Stomach Neoplasms 64 Neoplasm Metastasis 51 Neoplasms 37 HER2-positive Breast Cancer 29 Breast Neoplasms, Male 27 Colorectal Neoplasms 24 Brain Neoplasms 22 Esophageal Neoplasms 19 Carcinoma, Non-Small-Cell Lung 17 Inflammatory Breast Neoplasms 15 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 11 Ovarian Neoplasms 9 Endometrial Neoplasms 9 Colonic Neoplasms 9 Rectal Neoplasms 8 Urinary Bladder Neoplasms 7 Salivary Gland Neoplasms 7 Prostatic Neoplasms 7 Lung Neoplasms 7 Gallbladder Neoplasms 7 Adenocarcinoma Of Esophagus 7 Adenocarcinoma 7 Sarcoma 6 Pathologic Complete Response 6 Cardiotoxicity 6 Biliary Tract Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Breast Diseases 5

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡